35
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Disparities in Incidence of COVID-19 Among Underrepresented Racial/Ethnic Groups in Counties Identified as Hotspots During June 5–18, 2020 — 22 States, February–June 2020

      research-article
      , MSc, MPH 1 , , MD, PhD 1 , , , PhD 1 , , PhD 1 , , MD 1 , , PhD 1 , , PhD 1 , , PhD 1 , , PhD 1 , , MPH 1 , , DrPH 1 , , PhD 1 , , PhD 1 , , JD 1 , , PhD 1 , , DVM 1 , 1 , , PhD 1 , , MD 1 , , PhD 1 , COVID-19 State, Tribal, Local, and Territorial Response Team COVID-19 State, Tribal, Local, and Territorial Response Team COVID-19 State, Tribal, Local, and Territorial Response Team , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      Morbidity and Mortality Weekly Report
      Centers for Disease Control and Prevention

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          During January 1, 2020–August 10, 2020, an estimated 5 million cases of coronavirus disease 2019 (COVID-19) were reported in the United States.* Published state and national data indicate that persons of color might be more likely to become infected with SARS-CoV-2, the virus that causes COVID-19, experience more severe COVID-19–associated illness, including that requiring hospitalization, and have higher risk for death from COVID-19 ( 1 – 5 ). CDC examined county-level disparities in COVID-19 cases among underrepresented racial/ethnic groups in counties identified as hotspots, which are defined using algorithmic thresholds related to the number of new cases and the changes in incidence. † Disparities were defined as difference of ≥5% between the proportion of cases and the proportion of the population or a ratio ≥1.5 for the proportion of cases to the proportion of the population for underrepresented racial/ethnic groups in each county. During June 5–18, 205 counties in 33 states were identified as hotspots; among these counties, race was reported for ≥50% of cumulative cases in 79 (38.5%) counties in 22 states; 96.2% of these counties had disparities in COVID-19 cases in one or more underrepresented racial/ethnic groups. Hispanic/Latino (Hispanic) persons were the largest group by population size (3.5 million persons) living in hotspot counties where a disproportionate number of cases among that group was identified, followed by black/African American (black) persons (2 million), American Indian/Alaska Native (AI/AN) persons (61,000), Asian persons (36,000), and Native Hawaiian/other Pacific Islander (NHPI) persons (31,000). Examining county-level data disaggregated by race/ethnicity can help identify health disparities in COVID-19 cases and inform strategies for preventing and slowing SARS-CoV-2 transmission. More complete race/ethnicity data are needed to fully inform public health decision-making. Addressing the pandemic’s disproportionate incidence of COVID-19 in communities of color can reduce the community-wide impact of COVID-19 and improve health outcomes. This analysis used cumulative county-level data during February–June 2020, reported to CDC by jurisdictions or extracted from state and county websites and disaggregated by race/ethnicity. Case counts, which included both probable and laboratory-confirmed cases, were cross-referenced with counts from the HHS Protect database (https://protect-public.hhs.gov/). Counties missing race data for more than half of reported cases (126) were excluded from the analysis. § The proportion of the population for each county by race/ethnicity was calculated using data obtained from CDC WONDER ( 6 ). For each underrepresented racial/ethnic group, disparities were defined as a difference of ≥5% between the proportion of cases and the proportion of the population consisting of that group or a ratio of ≥1.5 for the proportion of cases to the proportion of the population in that racial/ethnic group. The county-level differences and ratios between proportion of cases and the proportion of population were used as a base for a simulation accounting for missing data using different assumptions of racial/ethnic distribution of cases with unknown race/ethnicity. An intercept-only logistic regression model was estimated for each race/ethnicity category and county to obtain the intercept regression coefficient and standard error. The simulation used the logistic regression-estimated coefficient and standard error to produce an estimated mean and confidence interval (CI) for the percentage difference between and ratio of proportions of cases and population. This simulation was done for each racial/ethnic group within each county. The lower bound of the CI was used to identify counties with disparities (as defined by percentage differences or ratio). The mean of the estimated differences and mean of the estimated ratios were calculated for all counties with disparities. Analyses were conducted using SAS software (version 9.4; SAS Institute). During June 5–18, a total of 205 counties in 33 states were identified as hotspots. These counties have a combined total population of 93.5 million persons, and approximately 535,000 cumulative probable and confirmed COVID-19 cases. Among the 205 identified hotspot counties, 79 (38.5%) counties in 22 states, with a combined population of 27.5 million persons and approximately 162,000 COVID-19 cases, had race data available for ≥50% of cumulative cases and were included in the analysis (range = 51.3%–97.4%). Disparities in cases were identified among underrepresented racial/ethnic groups in 76 (96.2%) analyzed counties (Table 1). Disparities among Hispanic populations were identified in approximately three quarters of hotspot counties (59 of 79, 74.7%) with approximately 3.5 million Hispanic residents (Table 2). Approximately 2.0 million black persons reside in 22 (27.8%) hotspot counties where black residents were disproportionately affected by COVID-19, approximately 61,000 AI/AN persons live in three (3.8%) hotspot counties where AI/AN residents were disproportionately affected by COVID-19, nearly 36,000 Asian persons live in four (5.1%) hotspot counties where Asian residents were disproportionately affected by COVID-19, and approximately 31,000 NHPI persons live in 19 (24.1%) hotspot counties where NHPI populations were disproportionately affected by COVID-19. TABLE 1 Total population and racial/ethnic disparities* in cumulative COVID-19 cases among 79 counties identified as hotspots during June 5–18, 2020, with any disparity identified — 22 states, February–June 2020 State No. of persons living in analyzed hotspot counties* No. of (col %) hotspot counties analyzed† No. of counties with disparities in COVID-19 cases among each racial/ethnic group§ Hispanic Black NHPI Asian AI/AN Alabama 500,000–1,000,000 1 (1.3) — 1 — — — Arizona 1,000,000–3,000,000 5 (6.3) 3 — — — 3 Arkansas 500,000–1,000,000 4 (5.1) 4 — 2 — — California 1,000,000–3,000,000 1 (1.3) 1 — — — — Colorado 100,000–500,000 1 (1.3) 1 — 1 — — Florida >3,000,000 6 (7.6) 3 2 — — — Georgia 100,000–500,000 1 (1.3) 1 — — — — Iowa 50,000–100,000 1 (1.3) 1 — — — — Kansas 500,000–1,000,000 2 (2.5) 2 — 2 — — Massachusetts 500,000–1,000,000 2 (2.5) — 2 — — — Michigan 1,000,000–3,000,000 5 (6.3) — 5 1 — — Minnesota <50,000 1 (1.3) 1 1 1 1 — Mississippi 100,000–500,000 2 (2.5) 1 2 — — — North Carolina >3,000,000 18 (22.8) 18 — 3 1 — Ohio 1,000,000–3,000,000 3 (3.8) 3 2 — 1 — Oregon 1,000,000–3,000,000 6 (7.6) 6 1 4 1 — South Carolina 1,000,000–3,000,000 9 (11.4) 6 4 2 — — Tennessee 500,000–1,000,000 3 (3.8) 3 — — — — Texas 500,000–1,000,000 2 (2.5) — 1 — — — Utah 1,000,000–3,000,000 4 (5.1) 4 1 3 — — Virginia <50,000 1 (1.3) — — — — — Wisconsin 100,000–500,000 1 (1.3) 1 — — — — Total (approximate) 27,500,000 79 (100) 59 22 19 4 3 Abbreviations: AI/AN = American Indian/Alaska Native; COVID-19 = coronavirus disease 2019; NHPI = Native Hawaiian/other Pacific Islanders. * Disparities were defined as percentage difference of ≥5% between the proportion of cases and the proportion of the population or a ratio ≥1.5 for the proportion of cases to the proportion of the population) for underrepresented racial/ethnic groups in each county. † Counties with race/ethnicity data available for ≥50% of cases. § Racial/ethnic groups are not mutually exclusive in a given county. TABLE 2 Number of persons in each racial/ethnic group living in 79 counties identified as hotspots during June 5–18, 2020 with disparities* — 22 states, February–June 2020 Racial/Ethnic group No. (%)† of counties with disparities§ identified Approximate no. of persons living in hotspot counties with disparities Hispanic/Latino 59 (74.7) 3,500,000 Black/African American 22 (27.8) 2,000,000 American Indian/Alaska Native 3 (3.8) 61,000 Asian 4 (5.1) 36,000 Native Hawaiian/Other Pacific Islander 19 (24.1) 31,000 Total — 5,628,000 Abbreviation: COVID-19 = coronavirus disease 2019. * Disparities were defined as percentage difference of ≥5% between the proportion of cases and the proportion of the population or a ratio ≥1.5 for the proportion of cases to the proportion of the population) for underrepresented racial/ethnic groups in each county. † Percentage of the 79 counties. § Disparities are in respective racial/ethnic groups and are not mutually exclusive; some counties had disparities in more than one racial/ethnic group. The mean of the estimated differences between the proportion of cases and proportion of the population consisting of each underrepresented racial/ethnic group in all counties with disparities ranged from 4.5% (NHPI) to 39.3% (AI/AN) (Table 3). The mean of the estimated ratio of the proportion of cases to the proportions of population were also generated for each underrepresented racial/ethnic group and ranged from 2.3 (black) to 8.5 (NHPI). TABLE 3 Proportion of cumulative COVID-19 cases compared with proportion of population in 79 counties identified as hotspots during June 5–18, 2020 with racial/ethnic disparities* — 22 states February–June 2020 Racial/Ethnic group Mean of estimated differences, † % (range) Mean of estimated ratios of proportion of cases to proportion of population§ (range) Hispanic/Latino 30.2 (8.0–68.2) 4.4 (1.2–14.6) Black/African American 14.5 (2.3–31.7) 2.3 (1.2–7.0) American Indian/Alaska Native 39.3 (16.4–57.9) 4.2 (1.9–6.4) Asian 4.7 (2.7–6.8) 2.9 (2.0–4.7) Native Hawaiian/Other Pacific Islander 4.5 (0.1–31.5) 8.5 (2.7–18.4) Abbreviation: COVID-19 = coronavirus disease 2019.
* Disparities were defined as percentage difference of ≥5% between the proportion of cases and the proportion of the population or a ratio ≥1.5 for the proportion of cases to the proportion of the population) for underrepresented racial/ethnic groups in each county. † The mean of the estimated differences between the proportion of cases in a given racial/ethnic group and the proportion of persons in that racial/ethnic group in the overall population among all counties with disparities identified by the analysis. For example, if Hispanic/Latino persons make up 20% of the population in a given county and 30% of the cases in that county, then the difference would be 10% and the county is considered to have a disparity. § The ratio of the estimated proportion of cases to the proportion of population for each racial/ethnic group among all counties with disparities identified by the analysis. For example, if American Indian/Alaskan Native persons made up 0.5% of the population in a given county and 1.5% of the cases in that county, then the ratio of proportions would be 3.0, and the county is considered to have a disparity. Discussion These findings illustrate the disproportionate incidence of COVID-19 among communities of color, as has been shown by other studies, and suggest that a high percentage of cases in hotspot counties are among persons of color ( 1 – 5 , 7 ). Among all underrepresented racial/ethnic groups in these hotspot counties, Hispanic persons were the largest group living in hotspot counties with a disparity in cases identified within that population (3.5 million persons). This finding is consistent with other evidence highlighting the disproportionate incidence of COVID-19 among the Hispanic population ( 2 , 7 ). The disproportionate incidence of COVID-19 among black populations is well documented ( 1 – 3 ). The findings from this analysis align with other data indicating that black persons are overrepresented among COVID-19 cases, associated hospitalizations, and deaths in the United States. The analysis found few counties with disparities among AI/AN populations. This finding is likely attributable to the smaller proportions of cases and populations of AI/AN identified in hotspot counties, as well as challenges with data for this group, including a lack of surveillance data and misclassification problems in large data sets. ¶ Asian populations were disproportionately affected by COVID-19 in a small number of hotspot counties. Few studies have assessed COVID-19 disparities among Asian populations in the United States.** The Asian racial category is broad, and further subgroup analyses might provide additional insights regarding the incidence of COVID-19 in this population. Disparities in COVID-19 cases in NHPI populations were identified in nearly one quarter of hotspot counties. For some hotspot counties with small NHPI populations, this finding might be related, in part, to the analytic methodology used. Using a ratio of ≥1.5 in the proportion of population and proportion of cases to indicate disparities is sensitive to small differences in these groups. More complete county-level race/ethnicity data are needed to fully evaluate the disproportionate incidence of COVID-19 among communities of color. Disparities in COVID-19–associated mortality in hotspot counties were not assessed because the available county-level mortality data disaggregated by race/ethnicity were not sufficient to generate reliable estimates. Existing national analyses highlight disparities in mortality associated with COVID-19; similar patterns are likely to exist at the county level ( 5 ). As more complete data are made available in the future, county-level analyses examining disparities in mortality might be possible. COVID-19 disparities among underrepresented racial/ethnic groups likely result from a multitude of conditions that lead to increased risk for exposure to SARS-CoV-2, including structural factors, such as economic and housing policies and the built environment, †† and social factors such as essential worker employment status requiring in-person work (e.g., meatpacking, agriculture, service, and health care), residence in multigenerational and multifamily households, and overrepresentation in congregate living environments with an increased risk for transmission ( 4 , 7 – 9 ). Further, long-standing discrimination and social inequities might contribute to factors that increase risk for severe disease and death, such as limited access to health care, underlying medical conditions, and higher levels of exposure to pollution and environmental hazards §§ ( 4 ). The conditions contributing to disparities likely vary widely within and among groups, depending on location and other contextual factors. Rates of SARS-CoV-2 transmission vary by region and time, resulting in nonuniform disease outbreak patterns across the United States. Therefore, using epidemiologic indicators to identify hotspot counties currently affected by SARS-CoV-2 transmission can inform a data-driven emergency response. Tailoring strategies to control SARS-CoV-2 transmission could reduce the overall incidence of COVID-19 in communities. Using these data to identify disproportionately affected groups at the county level can guide the allocation of resources, development of culturally and linguistically tailored prevention activities, and implementation of focused testing efforts. The findings in this report are subject to at least five limitations. First, more than half of the hotspot counties did not report sufficient race data and were therefore excluded from the analysis. In addition, many hotspot counties included in the analyses were missing data on race for a significant proportion of cases (mean = 28.3%; range = 2.6%–48.7%). These data gaps might result from jurisdictions having to reconcile data from multiple sources for a large volume of cases while data collection and management processes are rapidly evolving. ¶¶ Second, health departments differ in the way race/ethnicity are reported, making comparisons across counties and states more difficult. Third, differences in how race/ethnicity data are collected (e.g., self-report versus observation) likely varies by setting and could lead to miscategorization. Fourth, differences in access to COVID-19 testing could lead to underestimates of prevalence in some underrepresented racial/ethnic populations. Finally, the number of cases that had available race/ethnicity data for the period of study of hotspots (June 5–18) was too small to generate reliable estimates, so cumulative case counts by county during February–June 2020 were used to identify disparities. This approach describes the racial/ethnic breakdown of cumulative cases only. Therefore, these data might not provide an accurate estimate of disparities during June 5–18, which could be under- or overestimated, or change over time. Developing culturally responsive, targeted interventions in partnership with trusted leaders and community-based organizations within communities of color might reduce disparities in COVID-19 incidence. Increasing the proportion of cases for which race/ethnicity data are collected and reported can help inform efforts in the short-term to better understand patterns of incidence and mortality. Existing health inequities amplified by COVID-19 highlight the need for continued investment in communities of color to address social determinants of health*** and structural racism that affect health beyond this pandemic ( 4 , 8 ). Long-term efforts should focus on addressing societal factors that contribute to broader health disparities across communities of color. Summary What is already known about this topic? Long-standing health and social inequities have resulted in increased risk for infection, severe illness, and death from COVID-19 among communities of color. What is added by this report? Among 79 counties identified as hotspots during June 5–18, 2020 that also had sufficient data on race, a disproportionate number of COVID-19 cases among underrepresented racial/ethnic groups occurred in almost all areas during February–June 2020. What are the implications for public health practice? Identifying health disparities in COVID-19 hotspot counties can inform testing and prevention efforts. Addressing the pandemic’s disproportionate incidence among communities of color can improve community-wide health outcomes related to COVID-19.

          Related collections

          Most cited references6

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020

          The coronavirus disease 2019 (COVID-19) pandemic resulted in 5,817,385 reported cases and 362,705 deaths worldwide through May, 30, 2020, † including 1,761,503 aggregated reported cases and 103,700 deaths in the United States. § Previous analyses during February–early April 2020 indicated that age ≥65 years and underlying health conditions were associated with a higher risk for severe outcomes, which were less common among children aged 10% of persons in this age group. TABLE 2 Reported underlying health conditions* and symptoms † among persons with laboratory-confirmed COVID-19, by sex and age group — United States, January 22–May 30, 2020 Characteristic No. (%) Total Sex Age group (yrs) Male Female ≤9 10–19 20–29 30–39 40–49 50–59 60–69 70–79 ≥80 Total population 1,320,488 646,358 674,130 20,458 49,245 182,469 214,849 219,139 235,774 179,007 105,252 114,295 Underlying health condition§ Known underlying medical condition status* 287,320 (21.8) 138,887 (21.5) 148,433 (22.0) 2,896 (14.2) 7,123 (14.5) 27,436 (15.0) 33,483 (15.6) 40,572 (18.5) 54,717 (23.2) 50,125 (28.0) 34,400 (32.7) 36,568 (32.0) Any cardiovascular disease¶ 92,546 (32.2) 47,567 (34.2) 44,979 (30.3) 78 (2.7) 164 (2.3) 1,177 (4.3) 3,588 (10.7) 8,198 (20.2) 16,954 (31.0) 21,466 (42.8) 18,763 (54.5) 22,158 (60.6) Any chronic lung disease 50,148 (17.5) 20,930 (15.1) 29,218 (19.7) 363 (12.5) 1,285 (18) 4,537 (16.5) 5,110 (15.3) 6,127 (15.1) 8,722 (15.9) 9,200 (18.4) 7,436 (21.6) 7,368 (20.1) Renal disease 21,908 (7.6) 12,144 (8.7) 9,764 (6.6) 21 (0.7) 34 (0.5) 204 (0.7) 587 (1.8) 1,273 (3.1) 2,789 (5.1) 4,764 (9.5) 5,401 (15.7) 6,835 (18.7) Diabetes 86,737 (30.2) 45,089 (32.5) 41,648 (28.1) 12 (0.4) 225 (3.2) 1,409 (5.1) 4,106 (12.3) 9,636 (23.8) 19,589 (35.8) 22,314 (44.5) 16,594 (48.2) 12,852 (35.1) Liver disease 3,953 (1.4) 2,439 (1.8) 1,514 (1.0) 5 (0.2) 19 (0.3) 132 (0.5) 390 (1.2) 573 (1.4) 878 (1.6) 1,074 (2.1) 583 (1.7) 299 (0.8) Immunocompromised 15,265 (5.3) 7,345 (5.3) 7,920 (5.3) 61 (2.1) 146 (2.0) 646 (2.4) 1,253 (3.7) 2,005 (4.9) 3,190 (5.8) 3,421 (6.8) 2,486 (7.2) 2,057 (5.6) Neurologic/Neurodevelopmental disability 13,665 (4.8) 6,193 (4.5) 7,472 (5.0) 41 (1.4) 113 (1.6) 395 (1.4) 533 (1.6) 734 (1.8) 1,338 (2.4) 2,006 (4.0) 2,759 (8.0) 5,746 (15.7) Symptom§ Known symptom status† 373,883 (28.3) 178,223 (27.6) 195,660 (29.0) 5,188 (25.4) 12,689 (25.8) 51,464 (28.2) 59,951 (27.9) 62,643 (28.6) 70,040 (29.7) 52,178 (29.1) 28,583 (27.2) 31,147 (27.3) Fever, cough, or shortness of breath 260,706 (69.7) 125,768 (70.6) 134,938 (69.0) 3,278 (63.2) 7,584 (59.8) 35,072 (68.1) 42,016 (70.1) 45,361 (72.4) 51,283 (73.2) 37,701 (72.3) 19,583 (68.5) 18,828 (60.4) Fever †† 161,071 (43.1) 80,578 (45.2) 80,493 (41.1) 2,404 (46.3) 4,443 (35.0) 20,381 (39.6) 25,887 (43.2) 28,407 (45.3) 32,375 (46.2) 23,591 (45.2) 12,190 (42.6) 11,393 (36.6) Cough 187,953 (50.3) 89,178 (50.0) 98,775 (50.5) 1,912 (36.9) 5,257 (41.4) 26,284 (51.1) 31,313 (52.2) 34,031 (54.3) 38,305 (54.7) 27,150 (52.0) 12,837 (44.9) 10,864 (34.9) Shortness of breath 106,387 (28.5) 49,834 (28.0) 56,553 (28.9) 339 (6.5) 2,070 (16.3) 13,649 (26.5) 16,851 (28.1) 18,978 (30.3) 21,327 (30.4) 16,018 (30.7) 8,971 (31.4) 8,184 (26.3) Myalgia 135,026 (36.1) 61,922 (34.7) 73,104 (37.4) 537 (10.4) 3,737 (29.5) 21,153 (41.1) 26,464 (44.1) 28,064 (44.8) 28,594 (40.8) 17,360 (33.3) 6,015 (21.0) 3,102 (10.0) Runny nose 22,710 (6.1) 9,900 (5.6) 12,810 (6.5) 354 (6.8) 1,025 (8.1) 4,591 (8.9) 4,406 (7.3) 4,141 (6.6) 4,100 (5.9) 2,671 (5.1) 923 (3.2) 499 (1.6) Sore throat 74,840 (20.0) 31,244 (17.5) 43,596 (22.3) 664 (12.8) 3,628 (28.6) 14,493 (28.2) 14,855 (24.8) 14,490 (23.1) 13,930 (19.9) 8,192 (15.7) 2,867 (10.0) 1,721 (5.5) Headache 128,560 (34.4) 54,721 (30.7) 73,839 (37.7) 785 (15.1) 5,315 (41.9) 23,723 (46.1) 26,142 (43.6) 26,245 (41.9) 26,057 (37.2) 14,735 (28.2) 4,163 (14.6) 1,395 (4.5) Nausea/Vomiting 42,813 (11.5) 16,549 (9.3) 26,264 (13.4) 506 (9.8) 1,314 (10.4) 6,648 (12.9) 7,661 (12.8) 8,091 (12.9) 8,737 (12.5) 5,953 (11.4) 2,380 (8.3) 1,523 (4.9) Abdominal pain 28,443 (7.6) 11,553 (6.5) 16,890 (8.6) 349 (6.7) 978 (7.7) 4,211 (8.2) 5,150 (8.6) 5,531 (8.8) 6,134 (8.8) 3,809 (7.3) 1,449 (5.1) 832 (2.7) Diarrhea 72,039 (19.3) 32,093 (18.0) 39,946 (20.4) 704 (13.6) 1,712 (13.5) 9,867 (19.2) 12,769 (21.3) 13,958 (22.3) 15,536 (22.2) 10,349 (19.8) 4,402 (15.4) 2,742 (8.8) Loss of smell or taste 31,191 (8.3) 12,717 (7.1) 18,474 (9.4) 67 (1.3) 1,257 (9.9) 6,828 (13.3) 6,907 (11.5) 6,361 (10.2) 5,828 (8.3) 2,930 (5.6) 775 (2.7) 238 (0.8) Abbreviation: COVID-19 = coronavirus disease 2019. * Status of underlying health conditions known for 287,320 persons. Status was classified as “known” if any of the following conditions were reported as present or absent: diabetes mellitus, cardiovascular disease (including hypertension), severe obesity (body mass index ≥40 kg/m2), chronic renal disease, chronic liver disease, chronic lung disease, immunocompromising condition, autoimmune condition, neurologic condition (including neurodevelopmental, intellectual, physical, visual, or hearing impairment), psychologic/psychiatric condition, and other underlying medical condition not otherwise specified. † Symptom status was known for 373,883 persons. Status was classified as “known” if any of the following symptoms were reported as present or absent: fever (measured >100.4°F [38°C] or subjective), cough, shortness of breath, wheezing, difficulty breathing, chills, rigors, myalgia, rhinorrhea, sore throat, chest pain, nausea or vomiting, abdominal pain, headache, fatigue, diarrhea (≥3 loose stools in a 24-hour period), or other symptom not otherwise specified on the form. § Responses include data from standardized fields supplemented with data from free-text fields. Information for persons with loss of smell or taste was exclusively extracted from a free-text field; therefore, persons exhibiting this symptom were likely underreported. ¶ Includes persons with reported hypertension. ** Includes all persons with at least one of these symptoms reported. †† Persons were considered to have a fever if information on either measured or subjective fever variables if “yes” was reported for either variable. Among 287,320 (22%) cases with data on individual underlying health conditions, those most frequently reported were cardiovascular disease (32%), diabetes (30%), and chronic lung disease (18%) (Table 2); the reported proportions were similar among males and females. The frequency of conditions reported varied by age group: cardiovascular disease was uncommon among those aged ≤39 years but was reported in approximately half of the cases among persons aged ≥70 years. Among 63,896 females aged 15–44 years with known pregnancy status, 6,708 (11%) were reported to be pregnant. Among the 1,320,488 cases, outcomes for hospitalization, ICU admission, and death were available for 46%, 14%, and 36%, respectively. Overall, 184,673 (14%) patients were hospitalized, including 29,837 (2%) admitted to the ICU; 71,116 (5%) patients died (Table 3). Severe outcomes were more commonly reported for patients with reported underlying conditions. Hospitalizations were six times higher among patients with a reported underlying condition than those without reported underlying conditions (45.4% versus 7.6%). Deaths were 12 times higher among patients with reported underlying conditions compared with those without reported underlying conditions (19.5% versus 1.6%). The percentages of males who were hospitalized (16%), admitted to the ICU (3%), and who died (6%) were higher than were those for females (12%, 2%, and 5%, respectively). The percentage of ICU admissions was highest among persons with reported underlying conditions aged 60–69 years (11%) and 70–79 years (12%). Death was most commonly reported among persons aged ≥80 years regardless of the presence of underlying conditions (with underlying conditions 50%; without 30%). TABLE 3 Reported hospitalizations,* , † intensive care unit (ICU) admissions, § and deaths ¶ among laboratory-confirmed COVID-19 patients with and without reported underlying health conditions, ** by sex and age — United States, January 22–May 30, 2020 Characteristic (no.) Outcome, no./total no. (%)†† Reported hospitalizations*,† (including ICU) Reported ICU admission§ Reported deaths¶ Among all patients Among patients with reported underlying health conditions Among patients with no reported underlying health conditions Among all patients Among patients with reported underlying health conditions Among patients with no reported underlying health conditions Among all patients Among patients with reported underlying health conditions Among patients with no reported underlying health conditions Sex Male (646,358) 101,133/646,358 (15.6) 49,503/96,839 (51.1) 3,596/42,048 (8.6) 18,394/646,358 (2.8) 10,302/96,839 (10.6) 864/42,048 (2.1) 38,773/646,358 (6.0) 21,667/96,839 (22.4) 724/42,048 (1.7) Female (674,130) 83,540/674,130 (12.4) 40,698/102,040 (39.9) 3,087/46,393 (6.7) 11,443/674,130 (1.7) 6,672/102,040 (6.5) 479/46,393 (1.0) 32,343/674,130 (4.8) 17,145/102,040 (16.8) 707/46,393 (1.5) Age group (yrs) ≤9 (20,458) 848/20,458 (4.1) 138/619 (22.3) 84/2,277 (3.7) 141/20,458 (0.7) 31/619 (5.0) 16/2,277 (0.7) 13/20,458 (0.1) 4/619 (0.6) 2/2,277 (0.1) 10–19 (49,245) 1,234/49,245 (2.5) 309/2,076 (14.9) 115/5,047 (2.3) 216/49,245 (0.4) 72/2,076 (3.5) 17/5,047 (0.3) 33/49,245 (0.1) 16/2,076 (0.8) 4/5,047 (0.1) 20–29 (182,469) 6,704/182,469 (3.7) 1,559/8,906 (17.5) 498/18,530 (2.7) 864/182,469 (0.5) 300/8,906 (3.4) 56/18,530 (0.3) 273/182,469 (0.1) 122/8,906 (1.4) 24/18,530 (0.1) 30–39 (214,849) 12,570/214,849 (5.9) 3,596/14,854 (24.2) 828/18,629 (4.4) 1,879/214,849 (0.9) 787/14,854 (5.3) 135/18,629 (0.7) 852/214,849 (0.4) 411/14,854 (2.8) 21/18,629 (0.1) 40–49 (219,139) 19,318/219,139 (8.8) 7,151/24,161 (29.6) 1,057/16,411 (6.4) 3,316/219,139 (1.5) 1,540/24,161 (6.4) 208/16,411 (1.3) 2,083/219,139 (1.0) 1,077/24,161 (4.5) 58/16,411 (0.4) 50–59 (235,774) 31,588/235,774 (13.4) 14,639/40,297 (36.3) 1,380/14,420 (9.6) 5,986/235,774 (2.5) 3,335/40,297 (8.3) 296/14,420 (2.1) 5,639/235,774 (2.4) 3,158/40,297 (7.8) 131/14,420 (0.9) 60–69 (179,007) 39,422/179,007 (22.0) 21,064/42,206 (49.9) 1,216/7,919 (15.4) 7,403/179,007 (4.1) 4,588/42,206 (10.9) 291/7,919 (3.7) 11,947/179,007 (6.7) 7,050/42,206 (16.7) 187/7,919 (2.4) 70–79 (105,252) 35,844/105,252 (34.1) 20,451/31,601 (64.7) 780/2,799 (27.9) 5,939/105,252 (5.6) 3,771/31,601 (11.9) 199/2,799 (7.1) 17,510/105,252 (16.6) 10,008/31,601 (31.7) 286/2,799 (10.2) ≥80 (114,295) 37,145/114,295 (32.5) 21,294/34,159 (62.3) 725/2,409 (30.1) 4,093/114,295 (3.6) 2,550/34,159 (7.5) 125/2,409 (5.2) 32,766/114,295 (28.7) 16,966/34,159 (49.7) 718/2,409 (29.8) Total (1,320,488) 184,673/1,320,488 (14.0) 90,201/198,879 (45.4) 6,683/88,441 (7.6) 29,837/1,320,488 (2.3) 16,974/198,879 (8.5) 1,343/88,441 (1.5) 71,116/1,320,488 (5.4) 38,812/198,879 (19.5) 1,431/88,441 (1.6) Abbreviation: COVID-19 = coronavirus disease 2019. * Hospitalization status was known for 600,860 (46%). Among 184,673 hospitalized patients, the presence of underlying health conditions was known for 96,884 (53%). † Includes reported ICU admissions. § ICU admission status was known for 186,563 (14%) patients among the total case population, representing 34% of hospitalized patients. Among 29,837 patients admitted to the ICU, the status of underlying health conditions was known for 18,317 (61%). ¶ Death outcomes were known for 480,565 (36%) patients. Among 71,116 reported deaths through case surveillance, the status of underlying health conditions was known for 40,243 (57%) patients. ** Status of underlying health conditions was known for 287,320 (22%) patients. Status was classified as “known” if any of the following conditions were noted as present or absent: diabetes mellitus, cardiovascular disease including hypertension, severe obesity body mass index ≥40 kg/m2, chronic renal disease, chronic liver disease, chronic lung disease, any immunocompromising condition, any autoimmune condition, any neurologic condition including neurodevelopmental, intellectual, physical, visual, or hearing impairment, any psychologic/psychiatric condition, and any other underlying medical condition not otherwise specified. †† Outcomes were calculated as the proportion of persons reported to be hospitalized, admitted to an ICU, or who died among total in the demographic group. Outcome underreporting could result from outcomes that occurred but were not reported through national case surveillance or through clinical progression to severe outcomes that occurred after time of report. Discussion As of May 30, a total of 1,761,503 aggregate U.S. cases of COVID-19 and 103,700 associated deaths were reported to CDC. Although average daily reported cases and deaths are declining, 7-day moving averages of daily incidence of COVID-19 cases indicate ongoing community transmission. ¶¶¶¶ The COVID-19 case data summarized here are essential statistics for the pandemic response and rely on information systems developed at the local, state, and federal level over decades for communicable disease surveillance that were rapidly adapted to meet an enormous, new public health threat. CDC aggregate counts are consistent with those presented through the Johns Hopkins University (JHU) Coronavirus Resource Center, which reported a cumulative total of 1,770,165 U.S. cases and 103,776 U.S. deaths on May 30, 2020.***** Differences in aggregate counts between CDC and JHU might be attributable to differences in reporting practices to CDC and jurisdictional websites accessed by JHU. Reported cumulative incidence in the case surveillance population among persons aged ≥20 years is notably higher than that among younger persons. The lower incidence in persons aged ≤19 years could be attributable to undiagnosed milder or asymptomatic illnesses among this age group that were not reported. Incidence in persons aged ≥80 years was nearly double that in persons aged 70–79 years. Among cases with known race and ethnicity, 33% of persons were Hispanic, 22% were black, and 1.3% were AI/AN. These findings suggest that persons in these groups, who account for 18%, 13%, and 0.7% of the U.S. population, respectively, are disproportionately affected by the COVID-19 pandemic. The proportion of missing race and ethnicity data limits the conclusions that can be drawn from descriptive analyses; however, these findings are consistent with an analysis of COVID-19–Associated Hospitalization Surveillance Network (COVID-NET) ††††† data that found higher proportions of black and Hispanic persons among hospitalized COVID-19 patients than were in the overall population ( 4 ). The completeness of race and ethnicity variables in case surveillance has increased from 20% to >40% from April 2 to June 2. Although reporting of race and ethnicity continues to improve, more complete data might be available in aggregate on jurisdictional websites or through sources like the COVID Tracking Project’s COVID Racial Data Tracker. §§§§§ The data in this report show that the prevalence of reported symptoms varied by age group but was similar among males and females. Fewer than 5% of persons were reported to be asymptomatic when symptom data were submitted. Persons without symptoms might be less likely to be tested for COVID-19 because initial guidance recommended testing of only symptomatic persons and was hospital-based. Guidance on testing has evolved throughout the response. ¶¶¶¶¶ Whereas incidence among males and females was similar overall, severe outcomes were more commonly reported among males. Prevalence of reported severe outcomes increased with age; the percentages of hospitalizations, ICU admissions, and deaths were highest among persons aged ≥70 years, regardless of underlying conditions, and lowest among those aged ≤19 years. Hospitalizations were six times higher and deaths 12 times higher among those with reported underlying conditions compared with those with none reported. These findings are consistent with previous reports that found that severe outcomes increased with age and underlying condition, and males were hospitalized at a higher rate than were females ( 2 , 4 , 5 ). The findings in this report are subject to at least three limitations. First, case surveillance data represent a subset of the total cases of COVID-19 in the United States; not every case in the community is captured through testing and information collected might be limited if persons are unavailable or unwilling to participate in case investigations or if medical records are unavailable for data extraction. Reported cumulative incidence, although comparable across age and sex groups within the case surveillance population, are underestimates of the U.S. cumulative incidence of COVID-19. Second, reported frequencies of individual symptoms and underlying health conditions presented from case surveillance likely underestimate the true prevalence because of missing data. Finally, asymptomatic cases are not captured well in case surveillance. Asymptomatic persons are unlikely to seek testing unless they are identified through active screening (e.g., contact tracing), and, because of limitations in testing capacity and in accordance with guidance, investigation of symptomatic persons is prioritized. Increased identification and reporting of asymptomatic cases could affect patterns described in this report. Similar to earlier reports on COVID-19 case surveillance, severe outcomes were more commonly reported among persons who were older and those with underlying health conditions ( 1 ). Findings in this report align with demographic and severe outcome trends identified through COVID-NET ( 4 ). Findings from case surveillance are evaluated along with enhanced surveillance data and serologic survey results to provide a comprehensive picture of COVID-19 trends, and differences in proportion of cases by racial and ethnic groups should continue to be examined in enhanced surveillance to better understand populations at highest risk. Since the U.S. COVID-19 response began in January, CDC has built on existing surveillance capacity to monitor the impact of illness nationally. Collection of detailed case data is a resource-intensive public health activity, regardless of disease incidence. The high incidence of COVID-19 has highlighted limitations of traditional public health case surveillance approaches to provide real-time intelligence and supports the need for continued innovation and modernization. Despite limitations, national case surveillance of COVID-19 serves a critical role in the U.S. COVID-19 response: these data demonstrate that the COVID-19 pandemic is an ongoing public health crisis in the United States that continues to affect all populations and result in severe outcomes including death. National case surveillance findings provide important information for targeted enhanced surveillance efforts and development of interventions critical to the U.S. COVID-19 response. Summary What is already known about this topic? Surveillance data reported to CDC through April 2020 indicated that COVID-19 leads to severe outcomes in older adults and those with underlying health conditions. What is added by this report? As of May 30, 2020, among COVID-19 cases, the most common underlying health conditions were cardiovascular disease (32%), diabetes (30%), and chronic lung disease (18%). Hospitalizations were six times higher and deaths 12 times higher among those with reported underlying conditions compared with those with none reported. What are the implications for public health practice? Surveillance at all levels of government, and its continued modernization, is critical for monitoring COVID-19 trends and identifying groups at risk for infection and severe outcomes. These findings highlight the continued need for community mitigation strategies, especially for vulnerable populations, to slow COVID-19 transmission.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 — Georgia, March 2020

            SARS-CoV-2, the novel coronavirus that causes coronavirus disease 2019 (COVID-19), was first detected in the United States during January 2020 ( 1 ). Since then, >980,000 cases have been reported in the United States, including >55,000 associated deaths as of April 28, 2020 ( 2 ). Detailed data on demographic characteristics, underlying medical conditions, and clinical outcomes for persons hospitalized with COVID-19 are needed to inform prevention strategies and community-specific intervention messages. For this report, CDC, the Georgia Department of Public Health, and eight Georgia hospitals (seven in metropolitan Atlanta and one in southern Georgia) summarized medical record–abstracted data for hospitalized adult patients with laboratory-confirmed* COVID-19 who were admitted during March 2020. Among 305 hospitalized patients with COVID-19, 61.6% were aged 0.99 Chronic kidney disease, without dialysis 32 (10.5) 2 (2.2) 12 (12.1) 18 (15.4) 0.003 24 (9.7) 8 (16.0) 0.21 Cancer 12 (3.9) 3 (3.4) 3 (3.0) 6 (5.1) 0.76 10 (4.0) 2 (4.0) >0.99 Rheumatologic or autoimmune condition 8 (2.6) 1 (1.1) 5 (5.1) 2 (1.7) 0.22 6 (2.4) 2 (4.0) 0.63 Abbreviations: BMI = body mass index; COPD = chronic obstructive pulmonary disease; COVID-19 = coronavirus disease 2019; IQR = interquartile range; N/A = not applicable. * Black was defined as non-Hispanic black race/ethnicity; other includes all other racial/ethnic groups. † P-values were calculated using Fisher’s exact tests for proportions. § Eight patients were excluded from race comparisons because race and ethnicity data were missing. ¶ Age ≥65 years was considered a high-risk condition. ** BMI data were missing for 13 patients. §§ Documented conditions included solid organ transplant (eight), human immunodeficiency virus infection (eight), cancer with chemotherapy receipt within the previous year (three), stem cell transplant (three), and leukemia (two); 16 patients were taking immunosuppressive medications. Among the 305 hospitalized patients, the median duration of hospitalization was 8.5 days and duration increased with age (Table 2). Intensive care unit (ICU) admission occurred among 119 (39.0%) patients and increased significantly with age group: among patients aged ≥65 years, 53.8% were admitted to an ICU (p 0.99 Vasopressor support 84 (27.5) 13 (14.6) 21 (21.2) 50 (42.7) 0.99 Outcome Discharged alive 233 (76.4) 85 (95.5) 83 (83.8) 65 (55.6) <0.001 192 (77.7) 34 (68.0) 0.15 Still hospitalized 24 (7.9) 1 (1.1) 7 (7.1) 16 (13.7) 0.002 18 (7.3) 6 (12.0) 0.26 Died** 48 (17.1) 3 (3.4) 9 (9.8) 36 (35.6) <0.001 37 (16.2) 10 (22.7) 0.28 Invasive mechanical ventilation or death** 86 (30.6) 16 (18.2) 22 (23.9) 48 (47.5) <0.001 69 (30.1) 16 (36.4) 0.48 Abbreviations: COVID-19 = coronavirus disease 2019; ICU = intensive care unit; IQR = interquartile range. * Black was defined as non-Hispanic black race/ethnicity; other includes all other racial/ethnic groups. † Eight patients were excluded from race comparisons because race and ethnicity data were missing. § P-values were calculated using Fisher’s exact tests for proportions and the Wilcoxon rank-sum test or the Kruskal-Wallis H test for medians. ¶ Continuous variables are presented as median (IQR). ** Among 281 total patients who were no longer hospitalized, 88 (31.3%) were aged 18–49 years, 92 (32.7%) were aged 50–64 years, and 101 (35.9%) were aged ≥65 years; among 273 patients with available race/ethnicity data who were no longer hospitalized, 229 (83.9%) were non-Hispanic black, and 44 (16.1) were of other race/ethnicity. Among 281 (92.1%) patients who were no longer hospitalized at the time of data abstraction, 48 (17.1%) died. Case fatality among patients aged 18–49 years, 50–64 years, and ≥65 years was 3.4%, 9.8%, and 35.6%, respectively (p<0.001). Black patients were not more likely than were nonblack patients to receive IMV, to die, or to experience the composite outcome of IMV or death (Figure 2). Among patients without high-risk conditions, 22.5% were admitted to the ICU, 15.0% received IMV, and 5.1% died while in the hospital. As of April 24, 2020, 24 (7.9%) patients remained hospitalized, including 14 (58.3%) in the ICU and nine (37.5%) on IMV. Overall, the estimated percentage of deaths among patients who received ICU care ranged from 37.0%, assuming all remaining ICU patients survived, to 48.7%, assuming all remaining ICU patients died. In an adjusted time-to-event analysis of IMV or death as a composite outcome, no significant difference was found between black and nonblack patients (HR = 0.63; 95% CI = 0.35–1.13). Discussion This report characterizing a cohort of hospitalized adults with COVID-19 in Georgia (primarily metropolitan Atlanta) found that most patients in the cohort were black, and black patients had a similar probability of receiving IMV or dying during hospitalization compared with nonblack patients. Although a larger proportion of older patients had worse outcomes (IMV or death), a considerable proportion of patients aged 18–64 years who lacked high-risk conditions received ICU-level care and died (23% and 5%, respectively). Estimated case fatality among patients who received ICU care was high (37%–49%) but comparable with that observed in a smaller case series of COVID-19 patients in the state of Washington ( 5 ). Among hospitalized patients, 26% lacked high-risk factors for severe COVID-19, and few patients (7%) lived in institutional settings before admission, suggesting that SARS-CoV-2 infection can cause significant morbidity in relatively young persons without severe underlying medical conditions. Community mitigation recommendations (e.g., social distancing) should be widely instituted, not only to protect older adults and those with underlying medical conditions, but also to prevent the spread of SARS-CoV-2 among persons in the general population who might not consider themselves to be at risk for severe illness ( 6 ). The proportion of hospitalized patients who were black was higher than expected based on overall hospitalizations. At four affiliated hospitals, which accounted for 67% of patients in the cohort, 80% of cohort patients were black compared with 47% of hospitalized patients overall during March 2020 (D. Murphy, personal communication, April 7, 2020). Similarly, COVID-NET, which conducts population-based surveillance for laboratory-confirmed COVID-19–associated hospitalizations across 14 sites nationwide, ¶ found that black persons were disproportionately represented among hospitalized patients with COVID-19 ( 7 ). It is important to continue ongoing efforts to understand why black persons are disproportionately hospitalized for COVID-19, including the role of social and economic factors (including occupational exposures) in SARS-CoV-2 acquisition risk. It is critical that public health officials ensure that prevention activities prioritize communities and racial groups most affected by COVID-19. The findings in this report are subject to at least three limitations. First, the data are from a convenience sample of hospitalized adult patients in metropolitan Atlanta and southern Georgia, and data collection for this assessment was limited by the intention to conduct the investigation quickly. These patients do not necessarily represent all hospitalized patients with COVID-19 at those hospitals, or within Georgia. Second, patients were not tracked after discharge in this investigation. Finally, race and ethnicity were abstracted from medical records, and methods for recording these categories might have differed across hospitals, which could result in misclassification. This report provides valuable clinical data on a large cohort of hospitalized patients. Although frequency of IMV and fatality did not differ by race, black patients were disproportionately represented among hospitalized patients, reflecting greater severity of COVID-19 among this population. Public officials should consider racial differences among patients affected by COVID-19 when planning prevention activities. Approximately one quarter of patients had no high-risk conditions, and 5% of these patients died, suggesting that all adults, regardless of underlying conditions or age, are at risk for serious COVID-19–associated illness. Summary What is already known about this topic? Older adults and persons with underlying medical conditions are at higher risk for severe COVID-19. Non-Hispanic black patients are overrepresented among hospitalized U.S. COVID-19 patients. What is added by this report? In a cohort of 305 hospitalized adults with COVID-19 in Georgia (primarily metropolitan Atlanta), black patients were overrepresented, and their clinical outcomes were similar to those of nonblack patients. One in four hospitalized patients had no recognized risk factors for severe COVID-19. What are the implications for public health practice? Prevention activities should prioritize communities and racial groups most affected by severe COVID-19. Increased awareness of the risk for serious illness among all adults, regardless of underlying medical conditions or age, is needed.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Characteristics Associated with Hospitalization Among Patients with COVID-19 — Metropolitan Atlanta, Georgia, March–April 2020

              On June 17, 2020, this report was posted online as an MMWR Early Release. The first reported U.S. case of coronavirus disease 2019 (COVID-19) was detected in January 2020 ( 1 ). As of June 15, 2020, approximately 2 million cases and 115,000 COVID-19–associated deaths have been reported in the United States.* Reports of U.S. patients hospitalized with SARS-CoV-2 infection (the virus that causes COVID-19) describe high proportions of older, male, and black persons ( 2 – 4 ). Similarly, when comparing hospitalized patients with catchment area populations or nonhospitalized COVID-19 patients, high proportions have underlying conditions, including diabetes mellitus, hypertension, obesity, cardiovascular disease, chronic kidney disease, or chronic respiratory disease ( 3 , 4 ). For this report, data were abstracted from the medical records of 220 hospitalized and 311 nonhospitalized patients aged ≥18 years with laboratory-confirmed COVID-19 from six acute care hospitals and associated outpatient clinics in metropolitan Atlanta, Georgia. Multivariable analyses were performed to identify patient characteristics associated with hospitalization. The following characteristics were independently associated with hospitalization: age ≥65 years (adjusted odds ratio [aOR] = 3.4), black race (aOR = 3.2), having diabetes mellitus (aOR = 3.1), lack of insurance (aOR = 2.8), male sex (aOR = 2.4), smoking (aOR = 2.3), and obesity (aOR = 1.9). Infection with SARS-CoV-2 can lead to severe outcomes, including death, and measures to protect persons from infection, such as staying at home, social distancing ( 5 ), and awareness and management of underlying conditions should be emphasized for those at highest risk for hospitalization with COVID-19. Measures that prevent the spread of infection to others, such as wearing cloth face coverings ( 6 ), should be used whenever possible to protect groups at high risk. Potential barriers to the ability to adhere to these measures need to be addressed. Patients were selected from six acute care hospitals and associated outpatient clinics affiliated with a single academic health care system in metropolitan Atlanta. Hospitalized patients were selected sequentially from hospital-provided lists of patients aged ≥18 years who were hospitalized with laboratory-confirmed COVID-19 (defined as a positive real-time reverse transcription–polymerase chain reaction [RT-PCR] test result for SARS-CoV-2) during March 1–30. The 220 selected hospitalized patients were described previously ( 2 ); hospitalizations included stays for observation and deaths that occurred in an emergency department (ED). All 311 nonhospitalized patients (i.e., evaluated at outpatient clinics or an ED and not admitted) aged ≥18 years with laboratory-confirmed COVID-19 during March 1–April 7, were included, unless they stayed for observation or died in an ED. During April 8–May 1, trained personnel abstracted information from electronic medical records on patient demographics, occupation, underlying conditions, and symptoms using REDCap software (version 8.8.0; Vanderbilt University) ( 7 ). This investigation was determined by CDC to be public health surveillance and by the Georgia Department of Public Health as an institutional review board–exempt public health evaluation. During March 1–April 7, 2020, the health care system operated a telephone triage line to manage incoming patients with COVID-19–compatible symptoms. Patients with signs of severe illness (e.g., severe shortness of breath, confusion, or hemoptysis) were directed to an ED. Other symptomatic persons could receive outpatient SARS-CoV-2 testing; however, testing was limited, and appointments were prioritized for health care personnel and persons considered to be at higher risk for severe COVID-19–associated illness (e.g., persons aged ≥65 years and those with underlying conditions, including diabetes mellitus, cardiovascular disease, and chronic respiratory disease). For analyses, race was categorized as black or other race; obesity was defined as body mass index ≥30 kg/m2; age was categorized as 18–44, 45–64, and ≥65 years; smoking was defined as being a current or former smoker; cardiovascular disease excluded hypertension alone; and chronic kidney disease included end stage renal disease. Health care personnel were classified as persons whose occupations included patient contact or possible exposure to infectious agents in a health care setting. † Univariable and multivariable logistic regressions were used to compare hospitalized with nonhospitalized patients; variables included age group, race, sex, smoking status, insurance status, obesity, hypertension, diabetes mellitus, cardiovascular disease, chronic respiratory disease, and chronic kidney disease. These variables were selected based upon risk factors for severe COVID-19 identified in other studies ( 3 , 4 ) rather than a defined statistical endpoint. Persons lacking a health care visit during which a medical history could be recorded (25) were excluded from analyses. Because of small sample sizes for some variables, Firth’s correction was used to provide bias-reduction ( 8 ). Because information on race was missing for nearly one quarter (23%) of nonhospitalized patients, sensitivity analyses were performed. Multivariable analyses were repeated and any patient with missing race was reclassified, first as black, then as other race. This method of sensitivity analysis was used to avoid implicit assumptions about the nature of missing data. Data were analyzed using SAS statistical software (version 9.4; SAS Institute). Compared with nonhospitalized patients (311), hospitalized patients (220) were older (median age = 61 years) and more frequently male (52%) and black (79%) (Table). Obesity, smoking, hypertension, diabetes mellitus, and chronic kidney disease were more prevalent among hospitalized patients than among nonhospitalized patients. Among those whose occupations were reported, nonhospitalized patients were more likely to be health care personnel (54%) than were hospitalized patients (4%). Fever or cough were commonly reported among both hospitalized and nonhospitalized patients, whereas shortness of breath was reported more often among hospitalized patients. Chills, headache, loss of smell or taste, or sore throat were reported more often among nonhospitalized patients. TABLE Characteristics of hospitalized and nonhospitalized patients with COVID-19 treated at six acute care hospitals and associated outpatient clinics in metropolitan Atlanta, Georgia, March 1–April 7, 2020 Demographic characteristic No. (%) of patients Nonhospitalized
(n = 311) Hospitalized
(n = 220) Sex Male 114 (36.7) 114 (51.8) Female 197 (63.3) 106 (48.2) Age group (yrs) Median age, yrs (IQR) 45.0 (33.0–58.0) 61.0 (45.0–70.0) 18–44 151 (48.6) 54 (24.6) 45–64 120 (38.6) 76 (34.6) ≥65 years 40 (12.9) 90 (40.9) Race White 90 (28.9) 29 (13.2) Black 139 (44.7) 174 (79.1) Other 10 (3.2) 7 (3.2) Missing race 72 (23.2) 10 (4.6) Ethnicity Hispanic 10 (3.2) 6 (2.7) Non-Hispanic* 197 (63.3) 203 (92.3) Missing ethnicity 104 (33.4) 11 (5.0) Occupation Health care personnel† 168 (54.0) 8 (3.6) Non-health care personnel 78 (25.1) 50 (22.7) Missing occupation 65 (20.9) 162 (73.6) Other characteristic Uninsured 20 (6.4) 22 (10.0) Missing insurance status 6 (1.9) 3 (1.4) Lives in a congregate living facility§ 1 (0.3) 12 (5.5) Pregnant 4 (1.3) 3 (1.4) Past or current smoking 37 (11.9) 54 (24.6) Missing smoking status 52 (16.7) 9 (4.1) Underlying condition Obesity¶ 104 (33.4) 123 (55.9) Missing BMI 84 (27.0) 11 (5.0) Cardiovascular disease 12 (3.9) 8 (3.6) Hypertension 101 (32.5) 142 (64.6) Diabetes mellitus 30 (9.7) 81 (36.8) Type 1 2 (0.6) 2 (0.9) Type 2 28 (9.0) 74 (33.6) Chronic respiratory disease 56 (18.0) 45 (20.5) Chronic kidney disease 7 (2.3) 38 (17.3) Chronic kidney disease without dialysis 6 (1.9) 24 (10.9) End stage renal disease 1 (0.3) 14 (6.4) Any transplant 1 (0.3) 10 (4.6) Liver disease 4 (1.3) 5 (2.3) HIV infection 10 (3.2) 5 (2.3) Cancer 28 (9.0) 6 (2.7) Rheumatological disease 4 (1.3) 6 (2.7) No. of underlying conditions** 0 169 (54.3) 44 (20.0) 1 88 (28.3) 77 (35.0) 2 44 (14.2) 65 (29.6) ≥3 10 (3.2) 34 (15.5) Symptoms at initial evaluation Fever†† 240 (77.2) 188 (85.5) Cough 275 (88.4) 180 (81.8) Shortness of breath (dyspnea) 135 (43.4) 149 (67.7) Headache 171 (55.0) 35 (15.9) Chills 178 (57.2) 58 (26.4) Arthralgia 44 (14.2) 9 (4.1) Myalgia 184 (59.2) 69 (31.4) Sore throat 146 (47.0) 21 (9.6) Loss of smell§§ 130 (41.8) 4 (1.8) Loss of taste 106 (34.1) 6 (2.7) Gastrointestinal symptoms¶¶ 137 (44.1) 88 (40.0) Median interval between symptom onset and testing, days (IQR) 4.0 (2.0–7.0) 6.0 (3.0–9.5) Abbreviations: BMI = body mass index; HIV = human immunodeficiency virus; IQR = interquartile range. * Includes non-Hispanic white and other races/ethnicities. † Includes any occupation with patient contact. § Includes nursing homes, assisted living facilities, shelters, and dormitories. ¶ BMI ≥30.0 kg/m2. ** Includes cardiovascular disease, hypertension, diabetes, chronic respiratory disease, and chronic kidney disease. †† Includes subjective or objective fever (≥100.4°F [38°C]). §§ Loss of smell or taste was first widely reported on April 23, 2020; differences in the periods of investigations between hospitalized and nonhospitalized patients might be responsible for differences in proportions reported. ¶¶ Includes abdominal pain, diarrhea, nausea, or vomiting. After controlling for age, sex, race, obesity, smoking status, insurance status, hypertension, diabetes mellitus, cardiovascular disease, chronic respiratory disease, and chronic kidney disease, characteristics independently associated with hospitalization were age ≥65 years (aOR = 3.4, 95% confidence interval [CI] = 1.6–7.4); black race (aOR = 3.2, 95% CI = 1.8–5.8); having diabetes mellitus (aOR = 3.1, 95% CI = 1.7–5.9); lack of insurance (aOR = 2.8, 95% CI 1.1–7.3); male sex (aOR = 2.4, 95% CI = 1.4–4.1); smoking (aOR = 2.3, 95% CI = 1.2–4.5); and obesity (aOR = 1.9, 95% CI = 1.1–3.3) (Figure). When missing race was reclassified as black or other race in sensitivity analyses, associations with hospitalization did not appreciably change for any variables. FIGURE Unadjusted and adjusted* odds ratios and 95% confidence intervals for hospitalizations in COVID-19 patients (n = 506 † ) evaluated at six acute care hospitals and associated outpatient clinics, by selected characteristics — metropolitan Atlanta, Georgia, March 1–April 7, 2020 Abbreviation: COVID-19 = coronavirus disease 2019. * Adjusted for age, sex, race, obesity, past or current smoking, insurance status, obesity, and other underlying conditions (hypertension, diabetes mellitus, cardiovascular disease, chronic respiratory disease, and chronic kidney disease). † Complete case analysis was used for multivariable analyses; therefore, n = 368 for the multivariable model. The figure is a logarithmic plot showing unadjusted and adjusted odds ratios and 95% confidence intervals for hospitalizations in 506 COVID-19 patients evaluated at six acute care hospitals and associated outpatient clinics in metropolitan Atlanta, Georgia, during March 1–April 7, 2020, by selected characteristics. Discussion Older age, as measured by age ≥65 years, was associated with hospitalization, consistent with previous findings ( 3 , 4 ). Hospitalized patients with COVID-19 were more likely to have diabetes mellitus and obesity than were nonhospitalized patients, suggesting a relationship between these underlying conditions and increased severity of illness. Diabetes mellitus has been determined to be associated with more severe illness in hospitalized patients with COVID-19 ( 4 ) and in persons with illness caused by Middle East respiratory syndrome coronavirus ( 9 ). Obesity has previously been reported to be overrepresented in hospitalized patients with COVID-19 ( 3 ) and associated with hospitalization ( 4 ). After controlling for other underlying conditions and patient characteristics, hypertension was no longer associated with hospitalization, suggesting that other underlying conditions or factors associated with hypertension might be partially responsible for the higher prevalence of hypertension in hospitalized COVID-19 patients. The COVID-19 pandemic has highlighted persistent health disparities in the United States. In a previous investigation of hospitalized patients in Georgia, including the subset of hospitalized patients reported here, the proportion of patients who were black was higher than expected based on overall hospitalizations during the same period ( 2 ). Racial and ethnic minority groups are at higher risk for severe complications from COVID-19 because of the increased prevalence of diabetes, cardiovascular disease, and other underlying conditions among racial and ethnic minority groups. § Social determinants of health might also contribute to the disproportionate incidence of COVID-19 in racial and ethnic minority groups, including factors related to housing, economic stability, and work circumstances. ¶ In the United States, black workers are more likely than other workers to be frontline industry or essential workers,** which increases their likelihood of infection with SARS-CoV-2 while performing their jobs. This and other social factors could contribute to the disproportionate diagnoses of COVID-19 among black persons in metropolitan Atlanta. Black race has previously been associated with increased hospitalization among COVID-19 patients ( 10 ); however, race has not been associated with mortality among patients who were hospitalized ( 2 , 10 ). The independent association between black race and hospitalization in this investigation remained, even when the analysis controlled for other characteristics (including diagnosed underlying conditions), suggesting underlying conditions alone might not account for the higher rate of hospitalization among black persons. This might indicate that black persons are more likely to be hospitalized because of more severe illness, or it might indicate that black persons are less likely to be identified in the outpatient setting, potentially reflecting differences in health care access or utilization or other factors not identified through medical record review. Additional research is needed to more fully understand the association between black race and hospitalization. CDC and state and local partners are working to ensure completeness of race and ethnicity data and will continue to analyze and report on racial and ethnic disparities to further elucidate factors and health disparities associated with COVID-19 incidence and illness severity. The findings in this report are subject to at least five limitations. First, although this investigation identified COVID-19 patients from a single health care system, hospitalized patients likely represent a broader population than nonhospitalized patients because those experiencing mild illness might have accessed outpatient services outside of this health care system or chosen not to seek care. Differences in these two populations caused by selection bias might therefore result in nonhospitalized patients differing beyond having milder illness than hospitalized patients. Thus, in this report, hospitalization status might not only represent severity of illness but also care seeking and potentially other confounding characteristics. Second, given that outpatient testing was prioritized for certain persons, older patients and those with underlying conditions might be overrepresented among outpatients receiving testing, resulting in underestimated odds ratios for hospitalization. In addition, overrepresentation of health care personnel in the outpatient setting could result in overestimation of odds ratios if health care personnel were disproportionately young or healthy. Third, outpatient visits did not always include a full medical history; thus, underlying conditions and other characteristics might be underreported. Fourth, data on age was stratified into groups, and because of sample size, smaller age group categories could not be explored. Finally, data on race, body mass index, and smoking status were missing for a substantial proportion of nonhospitalized patients. Data could not be disaggregated for other races or analyzed by ethnicity because of small sample sizes. This investigation found that age ≥65 years, black race, and having diabetes mellitus were independently associated with hospitalization. Among the underlying conditions included in the multivariable analysis, diabetes mellitus was most strongly associated with hospitalization. The reported association between black race and hospitalization, which remained even after controlling for diagnosed underlying conditions, suggests that underlying conditions alone might not account for the higher rate of hospitalization among black persons. Other factors that might explain higher rates of hospitalization include health care access, other social determinants of health, or the possibility of bias. Infection with SARS-CoV-2 can lead to severe outcomes, including death, and measures to protect persons from infection such as staying at home, social distancing ( 5 ), and awareness and management of underlying conditions should be emphasized for those at highest risk for hospitalization with COVID-19. To protect groups at high risk, measures that prevent the spread of infection to others, such as wearing cloth face coverings ( 6 ), should be used whenever possible. Potential barriers to the ability to adhere to these measures need to be addressed. Summary What is already known about this topic? Hospitalized COVID-19 patients are more commonly older, male, of black race, and have underlying conditions. Less is known about factors increasing risk for hospitalization. What is added by this report? Data for 220 hospitalized and 311 nonhospitalized COVID-19 patients from six metropolitan Atlanta hospitals and associated outpatient clinics found that older age, black race, diabetes, lack of insurance, male sex, smoking, and obesity were independently associated with hospitalization. What are the implications for public health practice? To reduce severe outcomes from COVID-19, measures to prevent infection with SARS-COV-2 should be emphasized for persons at highest risk for hospitalization with COVID-19. Potential barriers to the ability to adhere to these measures need to be addressed.
                Bookmark

                Author and article information

                Contributors
                Journal
                MMWR Morb Mortal Wkly Rep
                MMWR Morb. Mortal. Wkly. Rep
                WR
                Morbidity and Mortality Weekly Report
                Centers for Disease Control and Prevention
                0149-2195
                1545-861X
                21 August 2020
                21 August 2020
                : 69
                : 33
                : 1122-1126
                Affiliations
                [1 ]CDC COVID-19 Response Team.
                CDC
                CDC
                CDC
                CDC
                CDC
                CDC
                CDC
                CDC
                CDC
                CDC
                CDC
                CDC
                CDC
                CDC
                CDC
                Alabama Department of Public of Health
                Arkansas Department of Health
                California COVID-19 Response Team
                Colorado Department of Public Health and Environment
                Florida Department of Health
                Florida Department of Health
                Georgia Department of Public Health
                Georgia Department of Public Health
                Iowa Department of Public Health
                Kansas Department of Health & Environment
                Massachusetts Department of Public Health
                Michigan Department of Health and Human Services
                Minnesota Department of Health
                Mississippi State Department of Health
                Mississippi State Department of Health
                North Carolina Department of Health and Human Services
                Ohio Department of Health
                Oregon Health Authority Public Health Division
                South Carolina Department of Health and Environmental Control
                Tennessee Department of Health
                Texas Department of State Health Services
                Utah Department of Health
                Virginia Department of Health
                Wisconsin Department of Health Services.
                Author notes
                Corresponding author: Jessica N. Ricaldi, mpi7@ 123456cdc.gov .
                Article
                mm6933e1
                10.15585/mmwr.mm6933e1
                7439982
                32817602
                75cb546b-e0e6-4375-a929-d5aa0f9d2048

                All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

                History
                Categories
                Full Report

                Comments

                Comment on this article